Pricing Log in Create free account
Friday 6 November 2026 Export TGTX’s income statement to Excel — free account

TG Therapeutics, Inc.

TGTX Healthcare Biotechnology

TG Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $616.3 million, up 87.3% from fiscal 2024.

Revenue
+70.3%
EPS
−73.7%
Free cash flow
+427.1%
Total debt
+204.2%

Quarter to June 2026, against a year earlier

58.50 0.52 +0.90%
Market cap
$8.9B
P/E
19.1×
Fwd P/E
62.4×
Dividend yield
—
F-score
5/9
Altman Z
6.29
Beneish M
0.80
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

TG Therapeutics, Inc. 10-K filed Feb 27, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 5:05 PM ET · Document on sec.gov · Filing index

Red flags

  • Profit ahead of cash

    TG Therapeutics, Inc.’s net income ran ahead of its operating cash flow for a second year, by 44.4% of total assets

    10-K filed · The filing · sec.gov

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business, against the 10-K filed Mar 3, 2025: 16 added · 19 removed · 29 modified; 2 with only figures updated

  1. Modified · OVERVIEW

    TG Therapeutics is a fully-integratedfully integrated, commercial stage, biopharmaceuticalbiotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell mediated diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) for the treatment of to treat adult patients with relapsing forms of multiple sclerosis (RMS), to include including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults, as well as approval by the European Commission (EC) andfrom several regulatory agencies outside of the Medicines and Healthcare products Regulatory Agency (MHRA) U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom (UK), respectively. We also actively evaluate complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.